La Mounjaro: the facts you need before deciding

Does the way Mounjaro works actually matter to your choice?

Most people researching weight-loss injections hear the phrase "GLP-1" and assume that settles it. Mounjaro goes further. It is a dual agonist: it activates both the GLP-1 receptor and the GIP receptor, two distinct gut-hormone pathways involved in appetite regulation, blood-sugar control, and the rate at which your stomach empties. That twin action is what separates tirzepatide from every other licensed weight-loss medicine currently available in the UK. In plain terms, it speaks to two systems at once rather than one.

Why does this matter practically? In the SURMOUNT-1 trial (2,539 adults with obesity and without type 2 diabetes, followed for 72 weeks) those on the 15 mg dose lost around 20–21% of their body weight on average. A later head-to-head study, SURMOUNT-5, compared tirzepatide directly with semaglutide 2.4 mg and found tirzepatide produced a greater average reduction. These are meaningful differences, not rounding errors. Still, no trial average tells you what you will experience; that depends on the dose reached, how long treatment continues, what you eat, and how your own physiology responds. If you want to understand how tirzepatide works in more detail, including the receptor science, that page goes deeper on the mechanism. There is also a dedicated page exploring the origins of tirzepatide and the lizard venom question that often comes up when people first research the drug.

The mechanism is not an academic footnote. It shapes how your hunger feels on treatment, which side effects you are more or less likely to encounter, and why the titration schedule exists. Understanding the why makes it easier to stick with the early weeks, when adjustment effects are at their peak.

Who Mounjaro is actually licensed to treat in the UK

The UK licence for Mounjaro as a weight-management medicine covers adults with a BMI of 30 or above, or adults with a BMI of 27 or above who have at least one weight-related health condition, for example, high blood pressure, raised cholesterol, prediabetes, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds, in line with UK clinical guidance.

NICE's appraisal TA1026 sets the NHS commissioning criteria somewhat higher: a BMI of 35 or above alongside at least one weight-related comorbidity, with ethnic-background adjustments of 2.5 kg/m² throughout. If you do not meet those NHS thresholds, or you would rather not join a waiting list, a private prescription through a regulated clinic is the alternative route, subject to the same clinical assessment. The weight-loss treatments page explains how that process works at nume.

A BMI figure alone does not decide the matter. The prescriber reviews your full health picture: existing conditions, current medications, family history, and whether any contraindications apply. Medullary thyroid carcinoma or a personal or family history of MEN2, certain gastrointestinal conditions, and a history of pancreatitis all require careful prescriber discussion before treatment can proceed. Under-18s are not covered by the licence, and Mounjaro is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive.

The cost question, and what it actually includes

Pricing is one of the first things people search for, and it is worth being direct about it. Since Eli Lilly raised UK list prices from September 2025, typical private Mounjaro prices range from roughly £149 to £375 per month depending on the dose and the provider. The Eli Lilly UK price increase page covers the background to that shift if you want the detail. What varies most between providers is what the headline figure actually includes: some charge separately for the consultation, the prescription, delivery, and any follow-up support.

At nume, one price covers the clinical consultation, the prescription if approved, the medicine, next-working-day tracked delivery, and aftercare seven days a week. There are no subscription traps or automatic renewals; every repeat order goes through a fresh clinical review. We are not the cheapest option available, that is a deliberate position, not an oversight. For a prescription medicine, the supply chain, the clinical oversight, and the aftercare matter as much as the unit cost. If you are ordering around payday or before a bank holiday, it is worth knowing that orders placed before 12 pm on working days are dispatched the same day once clinically approved.

For a broader look at the different weight-loss treatment options available, including where Mounjaro sits alongside other approaches, that page provides a useful overview.

The side effects that shape the first few weeks

The most common side effects of Mounjaro are gastrointestinal: nausea, loose stools, constipation, indigestion, and sometimes vomiting or burping, particularly after starting or after a dose increase. For most people these effects are at their worst in the first days after each new dose and settle within a week or two. Eating smaller portions, staying well hydrated, and avoiding fatty or very rich meals can make a real difference in those early weeks. These are the things our prescribers mention most often.

Less common but serious effects include acute pancreatitis, severe stomach pain that reaches into the back, with or without vomiting, requires urgent medical assessment. Gallbladder-related symptoms, significant dehydration from persistent vomiting or diarrhoea, and allergic reactions are also documented. None of these are reasons to avoid the medicine, but they are reasons to know the warning signs before you start rather than after. Women using oral contraceptive pills should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide can reduce pill absorption; NHS guidance on this point applies specifically to tirzepatide and not equivalently to semaglutide.

If you have questions about a specific dose or what starting at 2.5 mg typically involves, the Mounjaro 2.5 mg page covers the starter-pen experience in practical terms. You can also read more about the full Mounjaro range for context on how the titration journey typically progresses, and if you are curious about how pens are labelled or identified, the page covering Mounjaro Y explains what that designation means. Suspected side effects can be reported at any point through the MHRA's Yellow Card scheme.

If any of this raises questions specific to your situation, speak to a prescriber. That conversation is the right starting point.